Left Ventricular Ejection Fraction Monitoring Adherence Rates: Why So Low?

Chau T. Dang, Anne Blaes, Filipa Lynce, Sandra M. Swain, Susan Dent

Research output: Contribution to journalArticlepeer-review

1 Scopus citations
Original languageEnglish (US)
Pages (from-to)1094-1097
Number of pages4
JournalJACC: Cardiovascular Imaging
Volume11
Issue number8
DOIs
StatePublished - Aug 2018

Bibliographical note

Funding Information:
Dr. Dang has received research funding to her institution from Roche/Genentech and PUMA. Dr. Lynce has received research support from Genentech, Pfizer, Bristol-Myers Squibb, and AstraZeneca. Dr. Swain has received honoraria and travel support from Roche; consulting support from AstraZeneca for DMC no payment to date, Genentech/Roche, Pieris Pharmaceuticals, and Inivata; travel/accommodations/expenses from Genentech/Roche, Inivata, and Caris; and investigator meeting meal from Novartis. Dr. Dent has received support from Hoffman La Roche. Dr. Blaes has reported that she has no relationships relevant to the contents of this paper to disclose.

Keywords

  • breast cancer
  • cardiotoxicity
  • trastuzumab

Cite this